Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 866

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 866
---
):

| ​                                                                         
 ​                                                                         | ​ |                  ​ 
 For the Year Ended |          ​ | ​ |    ​ |          ​ |
|:--------------------------------------------------------------------------|:--|-------------------:|-----------:|:--|-----:|-----------:|
| ​                                                                         | ​ |       December 31, |            |   |      |            |
| ​                                                                         | ​ |               2023 |            |   | 2022 |            |
| Numerator:                                                                | ​ |                  ​ |          ​ | ​ |    ​ |          ​ |
| Net loss attributable to common stockholders                              | ​ |                  $ |    -17,347 | ​ |    $ |    -20,542 |
| Denominator:                                                              | ​ |                  ​ |          ​ | ​ |    ​ |          ​ |
| Weighted-average common shares outstanding, basic and diluted             | ​ |                  ​ | 19,134,096 | ​ |    ​ | 19,116,342 |
| Net loss per share attributable to common stockholders, basic and diluted | ​ |                  $ |      -0.91 | ​ |    $ |      -1.07 |

The Company’s potentially dilutive securities, which include stock options to purchase common stock and Preferred Stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

| ​                                              
 ​                                              | ​ |                  ​ 
 For the Year Ended | ​ |          ​ |
|:-----------------------------------------------|:--|-------------------:|:--|-----------:|
| ​                                              | ​ |       December 31, |   |            |
| ​                                              | ​ |               2023 |   |       2022 |
| Preferred stock (as converted to common stock) | ​ |         29,555,538 | ​ | 29,555,538 |
| Stock options to purchase common stock         | ​ |          5,509,379 | ​ |  4,828,500 |

F-111

13. Commitments and Contingencies

Legal Matters

The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary